Abstract
After an initial wave of coronavirus disease 2019 (COVID-19) in Haiti in summer 2020 (primarily lineage B.1), seropositivity for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) was ~40%. Variant P.1 (gamma) was introduced in February 2021, with an initially limited introduction followed by exponential local dissemination within this unvaccinated population with prior exposure to earlier SARS-CoV-2 lineages.
All Keywords
【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, IgG, Coronavirus disease 2019, coronavirus, Local, Immunoglobulin G, Immunoglobulin, P.1, Seropositivity, dissemination, summer, lineages, Haiti, followed by, exposure to, acute respiratory syndrome, acute respiratory syndrome coronavirus, lineage B.1, initial, introduced, 【제목키워드】 coronavirus 2, emergence, P.1, Rapid, Gamma, respiratory,
【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, IgG, Coronavirus disease 2019, coronavirus, Local, Immunoglobulin G, Immunoglobulin, P.1, Seropositivity, dissemination, summer, lineages, Haiti, followed by, exposure to, acute respiratory syndrome, acute respiratory syndrome coronavirus, lineage B.1, initial, introduced, 【제목키워드】 coronavirus 2, emergence, P.1, Rapid, Gamma, respiratory,
{{{ 추상적인 }}}
2020년 여름 아이티에서 코로나바이러스 질병 2019(COVID-19)의 초기 물결(주로 혈통 B.1) 이후 항중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 면역글로불린 G(IgG)에 대한 혈청양성도는 ~ 40%. 변종 P.1(감마)은 2021년 2월에 도입되었으며, 초기에는 제한적으로 도입된 후 이전 SARS-CoV-2 계통에 노출된 이 미접종 집단 내에서 기하급수적으로 국지적으로 보급되었습니다.